The detection of ALK receptor tyrosine kinase (ALK), ROS proto-oncogen1, receptor tyrosine kinase (ROS1), ret proto-oncogen (RET), and MET proto-oncogen exon 14 skipping (<i>MET</i>Δ<i>ex14</i>) allows for the selection of specific kinase inhibitor treatment in patients with non-small cell lung cancer (NSCLC). Here, MET is linked to non-small cell lung carcinoma.